Join to View Full Profile
Massachusetts General Hospital55 Fruit StreetBoston, MA 02114
Phone+1 617-726-2862
Dr. Gainor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
Harvard Medical SchoolClass of 2008
Certifications & Licensure
MA State Medical License 2010 - 2025
American Board of Internal Medicine Medical Oncology
Clinical Trials
- SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) Start of enrollment: 2020 Apr 23
- Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Start of enrollment: 2015 Oct 01
Roles: Principal Investigator, Contact
- Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Oxidation of retromer complex controls mitochondrial translation.Junbing Zhang, Md Yousuf Ali, Harrison Byron Chong, Pei-Chieh Tien, James Woods
Nature. 2025-03-26 - Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer.Sarah Waliany, Jessica J Lin, Justin F Gainor
Trends in Cancer. 2025-03-01 - 1 citationsAuthor Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01
Press Mentions
Individualized Cancer Therapy Demonstrates Safety and Sustained Immune ResponsesAugust 8th, 2024- HER2 and Lung CancerJune 7th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
